Figure 6.

Fold changes in activity of Ras determined by elisa from the ventrolateral medulla obtained during phases I or II after rats had received a microinjection, bilaterally into RVLM, of Mev (10 nmol), given alone or in addition to pretreatment with immunoneutralization of phosphorylated Shc (pShc^Y239/240 Ab; 1:20 or pShc^Y317 Ab; 1:20) or pharmacological blockade of Grb2/SOS (SH3b-p; 25 fmol), Ras (FTA; 40 pmol or manumycin A; 40 pmol) or Raf-1 (GW5074; 40 pmol). Since comparable results were obtained from pretreatments with aCSF, 0.2% DMSO or normal goat serum, only one set of data is presented (Vehicle) in this and Figures 7–9 for clarity. Values are mean ± SEM of triplicate analyses on samples from four to six animals in each group. *P < 0.05 versus vehicle group and #P < 0.05 versus Mev group in the Scheffé's multiple-range analysis.